Hos overvægtige forsøgspersoner med type 2 diabetes, er den intraindividuelle variation sammenlignelig med, eller mindre end, subkutant administreret hurtigtvirkende humant insulin, hvad angår Cmax og AUC.
In obese subjects with type 2 diabetes, intrasubject variability was comparable to or less than that of subcutaneously administered fast-acting human insulin for Cmax and AUC.